

# Burden of Influenza in 4 Ecologically Distinct Regions of Peru: Household Active Surveillance of a Community Cohort, 2009–2015

Yeny O. Tinoco,<sup>1,2</sup> Eduardo Azziz-Baumgartner,<sup>3</sup> Timothy M. Uyeki,<sup>3</sup> Hugo R. Rázuri,<sup>1</sup> Matthew R. Kasper,<sup>1</sup> Candice Romero,<sup>1</sup> Maria E. Silva,<sup>1</sup> Mark P. Simons,<sup>1</sup> Giselle M. Soto,<sup>1</sup> Marc-Alain Widdowson,<sup>3</sup> Robert H. Gilman,<sup>2</sup> Daniel G. Bausch,<sup>1,4,a</sup> and Joel M. Montgomery<sup>1,5,a</sup>; for the Peru Influenza Cohorts Working Group<sup>b</sup>

<sup>1</sup>US Naval Medical Research Unit No. 6, Bellavista, Peru; <sup>2</sup>Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; <sup>3</sup>Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia; <sup>4</sup>Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana; and <sup>5</sup>Division of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, Georgia

**Background.** There are limited data on the burden of disease posed by influenza in low- and middle-income countries. Furthermore, most estimates of influenza disease burden worldwide rely on passive sentinel surveillance at health clinics and hospitals that lack accurate population denominators.

**Methods.** We documented influenza incidence, seasonality, health-system utilization with influenza illness, and vaccination coverage through active community-based surveillance in 4 ecologically distinct regions of Peru over 6 years. Approximately 7200 people in 1500 randomly selected households were visited 3 times per week. Naso- and oropharyngeal swabs were collected from persons with influenza-like illness and tested for influenza virus by real-time reverse-transcription polymerase chain reaction.

**Results.** We followed participants for 35 353 person-years (PY). The overall incidence of influenza was 100 per 1000 PY (95% confidence interval [CI], 97–104) and was highest in children aged 2–4 years (256/1000 PY [95% CI, 236–277]). Seasonal incidence trends were similar across sites, with 61% of annual influenza cases occurring during the austral winter (May–September). Of all participants, 44 per 1000 PY (95% CI, 42–46) sought medical care, 0.7 per 1000 PY (95% CI, 0.4–1.0) were hospitalized, and 1 person died (2.8/100 000 PY). Influenza vaccine coverage was 27% among children aged 6–23 months and 26% among persons aged ≥65 years.

**Conclusions.** Our results indicate that 1 in 10 persons develops influenza each year in Peru, with the highest incidence in young children. Active community-based surveillance allows for a better understanding of the true burden and seasonality of disease that is essential to plan the optimal target groups, timing, and cost of national influenza vaccination programs.

**Keywords.** influenza; household-based; community cohort; seasonality; healthcare-seeking behavior.

Although influenza is a major cause of morbidity and mortality in temperate countries [1, 2], data are limited on the burden of influenza disease in low- and middle-income countries (LMICs). Furthermore, throughout the world, most estimates of influenza disease burden are based upon data from passive surveillance conducted through medically attended visits [2–5], which may represent the minority of symptomatic cases. This is pertinent to estimating the disease burden in LMICs, where financial constraints often limit access to medical care [6]. For example, in Peru,

a South American LMIC, 34% of the population does not have health insurance and a substantive proportion of individuals do not seek care because they perceive their illness to be manageable through self-medication (29%–31%) or lack the time (23%–24%) or money (10%–15%) to seek care [7]. Furthermore, extreme variability in socioeconomic and ecological conditions between regions within LMICs may call into question the applicability of national-level estimates of disease burden to a given region.

Active surveillance at the household level can provide more accurate estimates of influenza incidence by including persons who do not seek medical care [4]. Household-based studies of influenza in high-income countries dating back to the 1970s have contributed to a better understanding of the public health impact of influenza and informed influenza prevention, and control strategies [8, 9]. In particular, such studies help focus resources toward high-risk groups, especially influenza vaccination, which is recommended by the World Health Organization's Strategic Advisory Group of Experts (WHO-SAGE) on Immunization for pregnant woman, children aged

Received 23 January 2017; editorial decision 8 June 2017; accepted 22 June 2017; published online August 9, 2017.

<sup>a</sup>D. G. B. and J. M. M. contributed equally to this work.

<sup>b</sup>Members of the Peru Influenza Cohorts Working Group are listed after the References.

Correspondence: Y. O. Tinoco, Virology and Emerging Infections Department, US Naval Medical Research Unit No. 6, Av. Venezuela Cdra. 36 s/n, Callao 2, Peru (yeny.o.tinoco.fn@mail.mil).

Clinical Infectious Diseases® 2017;65(9):1532–41

Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US. DOI: 10.1093/cid/cix565

6–59 months, the elderly, and those with high-risk conditions [10]. Similar active surveillance community-based studies are needed to assess the community impact of influenza and allocate resources in LMICs [4].

Influenza disease burden data are limited from South America [2, 11], a continent with diverse climactic and ecologic zones [12], and a wide range of influenza vaccination coverage (30%–90%) among risk groups [13]. Peru is a country with a wide range of ecosystems: desert, semiarid, highland valleys, and tropical rainforest [12]. Recent studies suggest that the economic burden caused by influenza in Peru is substantial among WHO-SAGE target groups [14]. Current policy in Peru recommends annual influenza vaccination of pregnant women, children aged 7–23 months, health workers, the elderly ( $\geq 65$  years), and people with comorbidities [15]. Implementation of these guidelines is incomplete and varies by region [16, 17]. To gain a thorough understanding of the disease burden and the epidemiologic pattern of influenza in Peru, we established an active community-based household surveillance cohort in 4 ecologically and demographically distinct regions of Peru. Here we report 6 years of data describing the incidence, seasonality, health system utilization, and vaccination coverage for influenza in these regions.

## METHODS

### Study Sites

We chose study sites to represent diverse ecosystems of Peru, considering also various logistical factors (Figure 1 and Table 1): (1) Lima, Peru's capital, located in a coastal desert, with the study site in a periurban community 25 km from the city center; (2) Cuzco, located in the Andes mountain highlands, with the study site near the city center; (3) Tumbes, located in a dry tropical forest habitat on the border with Ecuador, with the study site comprised of semirural communities on the outskirts of the city; and (4) Puerto Maldonado, located in Peru's southern Amazon Basin, with a warm tropical rainforest climate. This study site is comprised of small communities around the city. The study period was June 2009 through July 2015 for Lima, Cuzco, and Puerto Maldonado, and through July 2014 for Tumbes.

### Study Population and Design

We selected households randomly from publicly available census data for each community using computer-generated random numbers to arrive at an initial study target population of 1500 people per cohort site (approximately 375 households per site) in 2009 and 1800 the following years. An adult head of household as well as all household members were invited to participate in the study. A household member was defined as a person who had lived in the household for at least 2 weeks at the time of consideration of enrollment with no plans to move

in the next 2 months. Persons joining the household after study initiation were also invited to participate. Household members who could not be located within 1 month of follow-up or who declined to participate were excluded. To maintain the target population, we randomly selected replacement households for each cohort site once per year.

### Household Surveillance, Case Definitions, and Sample Collection

Study field workers (SFWs) visited each household 3 times per week year-round to assess for the presence of influenza-like illness (ILI) among participants. For persons aged  $\geq 5$  years, ILI was defined as oral temperature  $\geq 38^\circ\text{C}$  or a subjective history of fever plus cough or sore throat not already diagnosed as another condition [18]. For children aged  $< 5$  years, ILI definition also included rhinorrhea and/or nasal congestion. SFWs educated 2 adults in each household in the identification of ILI symptoms and use of a digital oral thermometer provided by the study.

When participants reported ILI, SFWs collected naso- and oropharyngeal swabs and placed both into a tube containing commercially universal viral transport medium. Specimens were refrigerated at approximately  $4^\circ\text{C}$  until the end of the day and were then stored at  $-80^\circ\text{C}$  at the study center. SFWs sent samples biweekly on dry ice for influenza virus testing at the US Naval Medical Research Unit No. 6 (NAMRU-6) laboratory in Lima.

ILI cases were followed up for 15 days (3 times per week) from symptoms onset to collect data on healthcare utilization, hospitalization, and outcome. Since 2011 (Lima, Tumbes, and Cuzco) and 2012 (Puerto Maldonado), SFWs recorded influenza vaccination twice a month by checking participants' immunization card and verifying influenza vaccination status by cross-referencing with health center records.

### Laboratory Methods

We performed real-time reverse-transcription polymerase chain reaction (rRT-PCR) assay of combined nasal and oropharyngeal swabs to diagnose influenza [19]. Nucleic acid was extracted using the QIAamp Viral RNA Isolation Kit (Qiagen, Valencia, California), amplified by using the Access RT-PCR System (Promega, Madison, Wisconsin), and tested by rRT-PCR using primers and probes for influenza A and B viruses based on protocols from the US Centers for Disease Control and Prevention and the WHO.

### Statistical Analyses

We determined total person-time accrued by participants, excluding time when participants were unavailable for follow-up. We estimated influenza incidence by dividing the number of influenza episodes by the total person-years or person-months of contribution. Episodes of ILI or influenza in the same individual were counted separately when they occurred at intervals of  $> 15$  days. We estimated the health system utilization



**Figure 1.** Map of Peru showing ecological regions and sites for the Peru Influenza Cohort Study, 2009–2015.

as the percentage of total episodes of influenza that were medically attended.

To define the months of influenza epidemic activity, we calculated the monthly proportion of samples testing positive for influenza virus from January 2011 to July 2015 (except for Tumbes, where surveillance ended in July 2014) and applied these to a logistic regression model [20] where the proportion of samples testing for influenza was dependent on the month and time of the year. We considered proportion exceeding the annual median for  $\geq 2$  consecutive months as epidemic [5, 20]. The influenza vaccine coverage rate was estimated by dividing the number of participants with verified influenza vaccination during 2011–2014 by the total person-years (PY) of contribution. Participants were considered vaccinated when they had received 2 vaccine doses (children aged 6–23 months) or 1 or more vaccine doses (participants aged  $>23$  months) in the

current year [15]. Ninety-five percent confidence intervals (CIs) were calculated using a Poisson distribution. We stratified incidence by age group categories across sites, seasons, and influenza virus type/subtype. We used Stata version 13 software for statistical analyses.

#### Ethics Considerations

The NAMRU-6 Ethics Committee approved this study (NMRC.D.2009.0005). Informed written consent was obtained from each adult participant or parent or guardian of a child at the time of enrollment.

## RESULTS

#### Demographic Characteristics

SFWs approached 3483 households and enrolled 14 050 participants in 2486 households (average of 4.7 persons/household)

**Table 1. Characteristics of Study Population and Sites, Peru Influenza Cohort Study, 2009–2015<sup>a</sup>**

Characteristic	Study Site									
	Lima		Cuzco		Tumbes		Puerto Maldonado		Total	
No. of Participants <sup>b</sup>	3296		3565		2685		4504		14 050	
Sex, female	1699	(52)	1830	(51)	1379	(51)	2395	(53)	7303	(52)
Age group, y										
<2	300	(9)	351	(10)	290	(11)	418	(9)	1359	(10)
2–4	220	(7)	232	(6)	170	(6)	376	(8)	998	(7)
5–11	401	(12)	447	(13)	327	(12)	713	(16)	1888	(13)
12–17	424	(13)	466	(13)	290	(11)	577	(13)	1757	(13)
18–49	1573	(48)	1637	(46)	1179	(44)	1930	(43)	6319	(45)
50–64	302	(9)	289	(8)	248	(10)	362	(8)	1201	(9)
≥65	76	(2)	143	(4)	181	(7)	128	(3)	528	(4)
Age range, y	0–115		0–106		0–98		0–92			
Geographic characteristic										
Description of ecosystem	Coast desert		Andes mountain highlands		Dry tropical forest		Amazon rainforest			
Study site	Pampas de San Juan de Miraflores		San Jeronimo		San Jacinto		Tambopata			
Population	57 238		31 687		7979		60 214			
Latitude	76°58'12.15"		71°53'00"		80°27'04"		77°32'			
Longitude	12°9'5.2"		13°32'24"		03°38'35"		12°36'			
Altitude, m	141		3244		36		139			
Average rainfall/y, mm	15		800		250		>1000			
Average temperature, C° (min–max)	19 (17–23)		13 (7–19)		25 (17–36)		28 (20–34)			
Average relative humidity, % (min–max)	82 (63–94)		55 (31–82)		80 (52–92)		78 (55–99)			

Data are presented as No. (%) unless otherwise indicated.

<sup>a</sup>June 2009 through July 2015 for Lima, Cuzco, and Puerto Maldonado and June 2009 through July 2014 for Tumbes.

<sup>b</sup>Study population at enrollment.

across 4 sites. A total of 7874 (56%) participants either were lost to follow-up because they moved out of the study area (64% [5046/7874]), voluntarily withdrew (29% [2318]) (usually when asked to participate for a second or third year), were excluded because an adult informant was unavailable to provide household information after 6 attempts to reach them (5% [382]), or died as a result of causes unrelated to influenza (2% [128]). The final analyses included data for participants totaling 35 353 PY, with a weekly median of 6357 PY (interquartile range [IQR], 6034–6596). Fifty-two percent of participants were female, 45% were 18–49 years old, and 17% were aged <5 years (Table 1).

#### Influenza-like Illness Incidence

There were 13 584 ILI episodes among 5745 participants for a rate of 384 ILIs/1000 PY (95% CI, 378–391) among all age groups (Table 2). The median age of ILI cases was 8 years (IQR, 3–23). Children aged <2 years had the highest ILI incidence (1697/1000 PY [95% CI, 1626–1771]) across sites and study years, with incidence subsequently steadily declining with increasing age (Table 3). ILI incidence was highest in Lima (404/1000 PY [95% CI, 392–417]) (Table 2).

#### Influenza Incidence and Seasonal Trends

A total of 12 827 samples (94% of samples collected) were tested for influenza viral RNA by rRT-PCR, of which 3542 (28%) were positive, including 1361 (38%) influenza A(H3N2), 1092 (31%) influenza B, 1081 (31%) influenza A(H1N1)pdm09, 4 (0.1%) seasonal influenza A(H1N1), and 3 (0.1%) coinfections with A(H1N1)pdm09 and A(H3N2) viruses. The median age of influenza cases was 11 years (IQR, 5–24). The incidence of influenza was 100/1000 PY (95% CI, 97–104) among all age groups (Table 2). The incidence was lowest in Cuzco (83/1000 PY [95% CI, 77–89]) and similar among the other study sites (range, 104–108/1000 PY) (Table 2). Children had the highest influenza incidence, peaking at age 2–4 years (256/1000 PY [95% CI, 236–277]), with a sharp drop after age 11 and then progressively diminishing with increasing age (Table 3).

The annual incidence of influenza among all age groups and sites ranged from 43/1000 PY in 2011 to 153/1000 PY in 2009 during the influenza A(H1N1) 2009 pandemic (Tables 2 and 3). There was a clear predominance of influenza A(H1N1)pdm09 in 2009, influenza A(H3N2) in 2010 and 2011, influenza B in 2012, influenza A(H1N1)pdm09 in 2013, and influenza A(H3N2) in 2015 (Figure 2).

**Table 2. Incidence of Influenza-like Illness and Laboratory-Confirmed Influenza Study Site and Year, Peru Influenza Cohort Study, 2009–2015<sup>a</sup>**

Incidence	Study Site				
	Lima	Cuzco	Tumbes	Puerto Maldonado	Total
Influenza-like illness per 1000 PY (95% CI)					
2009	524 (478–575)	194 (164–231)	615 (561–674)	294 (258–335)	415 (393–439)
2010	407 (378–440)	353 (324–383)	481 (449–516)	387 (357–419)	408 (392–424)
2011	256 (232–282)	281 (256–309)	261 (237–287)	238 (215–265)	260 (247–273)
2012	479 (447–514)	332 (305–362)	336 (310–365)	396 (365–430)	386 (371–401)
2013	509 (475–544)	498 (464–535)	341 (314–370)	510 (472–550)	460 (443–477)
2014	359 (331–390)	437 (405–472)	344 (308–383)	478 (437–523)	404 (387–422)
2015	275 (241–314)	411 (368–458)	...	426 (373–486)	363 (338–389)
2009–2015 <sup>a</sup>	404 (392–417)	369 (356–381)	376 (363–389)	387 (374–401)	384 (378–391)
Influenza A and B per 1000 PY (95% CI)					
2009	216 (187–250)	30 (19–46)	238 (205–276)	109 (88–136)	153 (140–168)
2010	140 (123–159)	114 (98–132)	162 (143–183)	124 (107–143)	135 (126–145)
2011	26 (19–36)	65 (53–78)	26 (19–35)	59 (47–73)	43 (39–49)
2012	114 (99–131)	63 (52–77)	121 (106–139)	122 (105–141)	105 (97–113)
2013	128 (112–147)	91 (77–107)	82 (70–97)	84 (70–102)	97 (90–105)
2014	63 (49–82)	73 (58–93)	77 (61–97)	99 (78–126)	77 (68–86)
2015	72 (55–93)	116 (94–142)	...	118 (92–152)	99 (87–114)
2009–2015 <sup>a</sup>	107 (101–114)	83 (77–89)	108 (101–115)	104 (97–111)	100 (97–104)
Medically attended influenza per 1000 PY (95% CI) <sup>b</sup>	52 (48–57)	29 (26–32)	61 (56–66)	34 (30–38)	44 (42–46)
Influenza-associated hospitalizations per 1000 PY (95% CI)	0.2 (.03–.7)	0.9 (.4–1.6)	0.4 (.1–1.0)	1.4 (.7–2.4)	0.7 (.4–1.0)
Health system utilization, % (95% CI) <sup>b</sup>	49 (39–58)	35 (26–46)	56 (47–65)	33 (25–43)	44 (35–54)
Influenza vaccinations per 100 PY (95% CI) <sup>c</sup>	10 (9.4–11)	7 (6–8)	16 (15–17)	7 (6–8)	10 (9.7–10.6)

Person-years: All sites: (35353), 2009 (3020), 2010 (6352), 2011 (6243), 2012 (6394), 2013 (6217), 2014 (5045), 2015 (2082). Lima: 2009 (847), 2010 (1644), 2011 (1568), 2012 (1652), 2013 (1651), 2014 (1558), 2015 (796). Cuzco: 2009 (674), 2010 (1571), 2011 (1596), 2012 (1583), 2013 (1557), 2014 (1523), 2015 (770). Tumbes: 2009 (740), 2010 (1625), 2011 (1645), 2012 (1702), 2013 (1713), 2014 (949). Puerto Maldonado: 2009 (759), 2010 (1512), 2011 (1434), 2012 (1458), 2013 (1295), 2014 (1014), 2015 (517).

Abbreviations: CI, confidence interval; PY, person-years.

<sup>a</sup>June 2009 through July 2015 for Lima, Cuzco, and Puerto Maldonado and June 2009 through July 2014 for Tumbes.

<sup>b</sup>Health system utilization: ratio of the medically attended influenza episodes over total cases of influenza (B/A) × 100.

<sup>c</sup>Complete years from 2011 to 2014 for Lima and Cuzco, 2011 to 2013 for Tumbes, and 2012 to 2014 for Puerto Maldonado.

Although differences were observed between the 4 study sites, the timing of peak influenza incidence and seasonality of influenza virus circulation was generally similar (Figure 3). Influenza

epidemics generally occurred each year during the austral winter (May–September), accounting for an average of 61% of the annual cases (Figure 3). However, temporal variation between

**Table 3. Incidence of Influenza-like Illness, Laboratory-Confirmed Influenza, Influenza-Associated Hospitalizations, and Influenza Vaccine Coverage by Age Category, Peru Influenza Cohort Study, 2009–2015, All Sites Combined<sup>a</sup>**

Age Group, y	Influenza-like Illness per 1000 PY <sup>a</sup>		Influenza A and B per 1000 PY <sup>a</sup>				Influenza Vaccination per 100 PY <sup>b</sup>			
	Overall		Overall		Medically Attended		Hospitalization		Overall	
	Incidence	(95% CI)	Incidence	(95% CI)	Incidence	(95% CI)	Incidence	(95% CI)	Rate	(95% CI)
<2	1697	(1626–1771)	214	(190–241)	138	(119–160)	4.8	(1.9–10)	27	(24–31)
2–4	1225	(1180–1271)	256	(236–277)	131	(117–146)	2.2	(.8–4.9)	25	(23–28)
5–11	588	(568–609)	204	(192–217)	97	(89–106)	0.4	(.1–1.2)	9	(8–10)
12–17	318	(302–335)	112	(103–123)	34	(29–40)	...	...	5.5	(4.7–6.5)
18–49	186	(180–193)	51	(48–55)	19	(17–21)	0.4	(.2–.8)	6.4	(6.0–6.9)
50–64	190	(177–204)	51	(45–59)	21	(17–26)	0.8	(.2–2.1)	13	(11–14)
≥65	196	(175–219)	36	(28–47)	16	(11–26)	0.6	(.03–3.1)	26	(23–29)
Overall	384	(378–391)	100	(97–104)	44	(42–46)	0.7	(.4–1.0)	10.2	(9.7–10.6)


Person-years by age group: <2 years (1253), 2–4 years (2264), 5–11 years (5317), 12–17 years (4480), 18–49 years (16518), 50–64 years (3922), ≥65 years (1599).

Abbreviations: CI, confidence interval; PY, person-years.

<sup>a</sup>June 2009 through July 2015 for Lima, Cuzco, and Puerto Maldonado and June 2009 through July 2014 for Tumbes.

<sup>b</sup>Complete years from 2011 to 2014 for Lima and Cuzco, 2011 to 2013 for Tumbes, and 2012 to 2014 for Puerto Maldonado.






**Figure 2.** Laboratory-confirmed influenza incidence per 1000 person-months by virus type and subtype and percentage of positives for influenza A and B, Peru Influenza Cohort Study, 2009–2015. Abbreviation: ILI, influenza-like illness.

sites was occasionally observed, most notably in Tumbes, where a bimodal pattern was seen, with a modest rise in influenza incidence during March through May (early austral winter) and

a larger second peak during late winter (September through November). There was also occasional notable interseason circulation of specific viruses at specific sites, such as the spike of



**Figure 3.** Predicted influenza activity in the Peru Influenza Cohorts. The red portion of each data line indicates the seasonal epidemic period; light red line is the median (June 2011 through July 2015 for Lima, Cuzco, and Puerto Maldonado and June 2011 through July 2014 for Tumbes).

influenza A(H3N2) virus infection in Lima during the summer (December through May) of 2012–2013.

#### Health System Utilization

Less than half (44% [95% CI, 35%–54%]) of participants with influenza sought medical care (either ambulatory or inpatient) (Table 2). The rate of at least 1 visit to a health center during a bout of influenza was 44/1000 PY (95% CI, 42–46). The highest rate of medically attended influenza was observed in children aged <2 years (138/1000 PY [95% CI, 119–160]) and the lowest was in older adults (16/1000 PY [95% CI, 11–26]) (Table 3). Health system utilization was higher in Tumbes (56% [95% CI, 47%–65%]) and Lima (49%

[95% CI, 39%–58%]) than in Cuzco (35% [95% CI, 26%–46%]) and Puerto Maldonado (33% [95% CI, 25%–43%]) (Table 3).

#### Influenza-Associated Hospitalizations and Deaths

The overall incidence of influenza-associated hospitalization was 0.7/1000 PY and was highest among children aged <2 years (4.8/1000 PY) (Table 3). Overall incidence of influenza-associated hospitalizations among adults ranged from 0.4 to 0.8/1000 PY. We identified only 1 influenza-associated death—a 42-year-old man without preexisting medical conditions who died during the 2009 pandemic from complications of influenza A(H1N1)pdm09 virus infection.

### Influenza Vaccination Rates

The overall vaccination rate was 10.2/100 PY (95% CI, 9.7–10.6) but varied among sites, being higher in Tumbes (16/100 PY [95% CI, 15–17]) and Lima (10/100 PY [95% CI, 9–11]) compared with Cuzco and Puerto Maldonado (both 7/100 PY [95% CI, 6–8]). Overall vaccination rates were similar in 2011 (11/100 PY [95% CI, 10–12]), 2012 (12/100 PY [95% CI, 11–13]), and 2013 (11/100 PY [95% CI, 10–12]) but lower in 2014 (3.5/100 PY [95% CI, 3–4]). Among all sites, influenza vaccination rates were similar among children aged <5 years (26/100 PY [95% CI, 24–28]) and the elderly (26/100 PY [95% CI, 23–29]) (Table 3).

### DISCUSSION

Extrapolating the 6 years of our active household surveillance study to the general population, we estimate that influenza virus infection caused approximately 1 in 10 persons to become ill each year in Peru. The incidence was especially high among children aged <5 years, ranging across study sites from 214 to 256/1000 PY, for whom influenza accounted for approximately 16% of all episodes of ILI. The observed influenza incidence in Peru was higher than estimates from Kenya (all ages: 7–9/1000 PY; children aged <5 years: 22–30/1000 PY) [21], China (all ages: 4–19/1000 PY; <5 years: 34–95/1000 PY) [22], and the United States (all ages: 10/1000 PY; <5 years: 4–13/1000 PY) [23]. The observed difference between Peru and other sites is likely explainable, in part, by the active surveillance strategy of our study; less than half (44%) of episodes of influenza resulted in medical care seeking, and would thus have been missed through routine passive surveillance health center–based approaches.

Comparable studies conducted using community-based active surveillance approaches such as ours are scarce. Estimates from studies in children aged <3 years in Bangladesh, Nicaragua, and the highlands of Peru show a similar annual influenza incidence (150–205/1000 PY) as we estimated in Peru [11, 24, 25]. However, to compare these estimates to the ones in our study, we should note that our study was designed to capture ILI episodes rather than acute respiratory illnesses and thus may have underestimated influenza illnesses that did not meet the ILI case definition. Our study is similar in scope and design to one conducted in the Amazon Basin of Peru from 2008 to 2009 that reported annual influenza incidence of 16/1000 PY among the general population and 37/1000 PY among children aged <5 years [26]. The higher overall influenza illness rates observed in our study may be due to our use of rRT-PCR rather than cell culture to diagnose influenza.

The finding of peak influenza incidence during the austral winter is consistent with previous reports [3, 5, 20]. Whether the distinct seasonal patterns noted in Tumbes, and the aberration in incidence of influenza A(H1N1)pdm09 virus infection in Cuzco in 2009, relate to climatic, behavioral, or vaccination coverage or timing remains to be determined. Cuzco is one of

Peru's top tourist destinations, which would make it particularly vulnerable to pandemic spread. The lower observed incidence there may simply reflect having missed the wave of earlier influenza A(H1N1)pdm09 virus introduction and associated disease before the study surveillance began in June 2009. Phylogenetic analysis of influenza A(H3N2) virus samples from this study demonstrated interseasonal extinction of Peruvian lineages, with extensive mixing with global clades, especially in Lima and Puerto Maldonado [27].

Despite similar influenza incidence between study sites, there were notable differences in the rates of health system utilization and influenza vaccination coverage. In Tumbes and Lima, approximately half of the influenza cases sought medical care compared to 35% or less in Cuzco and Puerto Maldonado. Lower health system utilization in Cuzco and Puerto Maldonado may have impacted influenza vaccination coverage, which was also lower in these 2 sites. These differences may be related to cultural practices, socioeconomic status, and access to healthcare—all factors that may be important to consider when public health officials estimate the burden of respiratory viruses from medically attended visits alone [28]. The burden of disease may be especially underestimated in countries where healthcare utilization is particularly low. For example, reported ambulatory healthcare utilization for ILI in Bangladesh in 2008–2010 was only 20% [29]. Influenza vaccination coverage was generally low for all age groups, but similar to that observed in other countries in Latin America [13]. Further studies to identify potential barriers and facilitators to healthcare utilization and influenza vaccination should be considered [30].

One percent of influenza episodes resulted in hospitalization in our study, with the highest rates among young children, although only 1 influenza-related death was noted. Similar hospitalization rates for influenza were reported from modeling estimations from Central American countries during 2009–2012 (0.2–3.6/1000 PY in children aged <5 years and 0.2–1.1/1000 PY in persons aged ≥65 years) [31]. Hospitalization rates among older adults in our study, however, were lower than in high-income countries (0.6/1000 PY vs 6–42/1000 PY) [32, 33]. We speculate these differences might be due to lower healthcare seeking among older adults in Peru compared with those in high-income settings. Despite these overall low rates of influenza-associated hospitalization and death, the high morbidity in children and resultant associated economic costs [14] nevertheless strongly support the WHO-SAGE recommendation for targeting young children for annual influenza vaccination [10]. Peru might also explore the potential value of expanding influenza vaccination to school-aged children (eg, 5–11 years) in hopes of an overall reduction of influenza-associated illness among all ages by indirect protection [34, 35]. Our seasonal incidence data suggest that the impact of influenza vaccine would be maximized by timing vaccination to



just before the primary epidemic period in Peru's austral winter, which is immediately preceded by Vaccination Week of the Americas, a Pan American Health Organization–led event that occurs every April [13].

Our study had limitations that likely resulted in an underestimation of the incidence of symptomatic influenza. We used an ILI case definition based on the presence of fever and, therefore, missed cases in which fever was not present, which frequently occurs in very young or old persons with influenza [36]. We also likely underestimated the burden of influenza because we did not collect respiratory specimens for laboratory testing from mildly ill or well household members for rRT-PCR or serum for influenza serological testing, and therefore did not assess subclinical and asymptomatic influenza virus infections as noted in other studies [37, 38]. Last, our study provides conservative estimates of influenza-associated hospitalizations and deaths, as it was designed to estimate the incidence of influenza-associated ILI.

Our study provides valuable estimates of the burden of influenza from a multisite, community-based active surveillance cohort reflecting different ecological niches in South America. Such estimates allow for a better understanding of the true burden and seasonality of influenza disease in the region that is essential to inform influenza prevention and control in priority groups (eg, young children and elderly) and to optimize resource allocation when designing similar studies, as well as the timing and economic benefit of national influenza vaccination programs [10]. The burden of influenza in Peru is comparable to that of countries that annually invest in influenza vaccination among WHO-SAGE target groups. The feasibility of similar approaches to improve influenza vaccine coverage in Peru should be explored.

## Notes

**Author contributions.** J. M. M., T. M. U., H. R. R., and Y. O. T. contributed to the conception and design of the study; Y. O. T. did the data analysis and wrote the first draft of the report. J. M. M., D. G. B., E. A.-B., T. M. U., and M. R. K. were involved in the revision of the manuscript for clarity and content. C. R., M. P. S., M. E. S., G. M. S., M.-A. W., and R. H. G. did critical revision of manuscript. All authors contributed to the interpretation of the results of the analysis and to the revision and final preparation of the report for submission.

**Acknowledgments.** The authors acknowledge the influenza staff from each of the sites in Lima, Cuzco, Tumbes, and Puerto Maldonado; and the community members of San Juan de Miraflores, San Jacinto, San Jeronimo, and Puerto Maldonado districts.

**Disclaimer.** The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the US Department of Defense, the US Centers for Disease Control and Prevention (CDC), or the US government. The study protocol was approved by the NAMRU-6 Institutional Review Board (protocol NMRCD.2009.005) in compliance with all applicable federal regulations governing the protection of human subjects.

**Financial support.** This work was supported by the NAMRU-6 Interagency agreement with the Centers for Disease Control and Prevention (CDC); the National Institutes of Health, Fogarty International Center (5D43TW007393-03 to Y. O. T.); and the US Department of Defense Global Emerging Infections System (I0082\_09\_LI).

**Potential conflicts of interest.** All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

## References

1. Nair H, Brooks WA, Katz M, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. *Lancet* 2011; 378:1917–30.
2. Cheng PY, Palekar R, Azziz-Baumgartner E, et al. Burden of influenza-associated deaths in the Americas, 2002–2008. *Influenza Other Respir Viruses* 2015;9(suppl 1):13–21.
3. Laguna-Torres VA, Gómez J, Ocaña V, et al. Influenza-like illness sentinel surveillance in Peru. *PLoS One* 2009; 4:e6118.
4. Monto AS, Comanor L, Shay DK, Thompson WW. Epidemiology of pandemic influenza: use of surveillance and modeling for pandemic preparedness. *J Infect Dis* 2006;194(suppl 2):S92–7.
5. Azziz-Baumgartner E, Dao CN, Nasreen S, et al. Seasonality, timing, and climate drivers of influenza activity worldwide. *J Infect Dis* 2012; 206:838–46.
6. Razuri H, Romero C, Tinoco Y, et al. Population-based active surveillance cohort studies for influenza: lessons from Peru. *Bull World Health Organ* 2012; 90:318–20.
7. Superintendencia Nacional de Salud (SUSALUD). Mundo IPRESS. Población no acude a realiza consultas en un establecimiento de Salud 2004–2013. Lima: Peruvian Ministry of Health, 2017. Available at: [http://portales.susalud.gob.pe/web/mundo-ipress/poblacion-no-acude?p\\_p\\_id=122\\_INSTANCE\\_OoVQI7nNPax8&p\\_p\\_lifecycle=0&p\\_p\\_state=normal&p\\_p\\_mode=view&p\\_p\\_col\\_id=column-3&p\\_p\\_col\\_count=2&p\\_r\\_p\\_564233524\\_resetCur=true&p\\_r\\_p\\_564233524\\_categoryId=64234](http://portales.susalud.gob.pe/web/mundo-ipress/poblacion-no-acude?p_p_id=122_INSTANCE_OoVQI7nNPax8&p_p_lifecycle=0&p_p_state=normal&p_p_mode=view&p_p_col_id=column-3&p_p_col_count=2&p_r_p_564233524_resetCur=true&p_r_p_564233524_categoryId=64234). Accessed 17 May 2017.
8. Monto AS, Malosh RE, Petrie JG, Thompson MG, Ohmit SE. Frequency of acute respiratory illnesses and circulation of respiratory viruses in households with children over 3 surveillance seasons. *J Infect Dis* 2014; 210:1792–9.
9. Monto AS. Global burden of influenza: what we know and what we need to know. *International Congress Series*. 2004;1263:3–11.
10. World Health Organization Strategic Advisory Group of Experts. Statement on influenza immunization. 2012. Available at: [http://www.who.int/influenza/vaccines/SAGE\\_information/en/](http://www.who.int/influenza/vaccines/SAGE_information/en/). Accessed 21 May 2015.
11. Budge PJ, Griffin MR, Edwards KM, et al; RESPIRA PERU Group. Impact of home environment interventions on the risk of influenza-associated ARI in Andean children: observations from a prospective household-based cohort study. *PLoS One* 2014; 9:e91247.
12. Food and Agriculture Organization of the United Nations (FAO). South America: ecological zones. In: *Global forest resources assessment 2000*. Available at: <http://www.fao.org/docrep/004/Y1997E/y1997e1b.htm>. Accessed 19 June 2016.
13. Ropero-Alvarez AM, El Omeiri N, Kurtis HJ, Danovaro-Holliday MC, Ruiz-Matus C. Influenza vaccination in the Americas: progress and challenges after the 2009 A(H1N1) influenza pandemic. *Hum Vaccin Immunother* 2016;1–9.
14. Tinoco YO, Azziz-Baumgartner E, Razuri H, et al. A population-based estimate of the economic burden of influenza in Peru, 2009–2010. *Influenza Other Respir Viruses* 2016;10:301–9.
15. Ministry of Health, Peru. Norma Técnica de Salud que establece el Esquema Nacional de Vacunación. Lima, Peru: Ministry of Health, 2013:61.
16. Hirve S, Lambach P, Paget J, Vandemaale K, Fitzner J, Zhang W. Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics—a systematic literature review. *Influenza Other Respir Viruses* 2016; 10:254–67.
17. Palache A, Oriol-Mathieu V, Fino M, Xydia-Charmanita M. Seasonal influenza vaccine dose distribution in 195 countries (2004–2013): little progress in estimated global vaccination coverage. *Vaccine* 2015; 33: 5598–605.
18. Tinoco Y, Razuri H, Ortiz EJ, et al; Peru Influenza Working Group. Preliminary population-based epidemiological and clinical data on 2009 pandemic H1N1 influenza A (pH1N1) from Lima, Peru. *Influenza Other Respir Viruses* 2009; 3:253–6.
19. World Health Organization. CDC protocol of real-time RT-PCR for influenza A(H1N1) 2009. Available at: [http://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR\\_SwineH1Assay-2009\\_20090430.pdf](http://www.who.int/csr/resources/publications/swineflu/CDCRealtimeRTPCR_SwineH1Assay-2009_20090430.pdf). Accessed 25 January 2012.
20. Durand LO, Cheng PY, Palekar R, et al. Timing of influenza epidemics and vaccines in the American tropics, 2002–2008, 2011–2014. *Influenza Other Respir Viruses* 2016;10:170–5.
21. Emukule GO, Khagayi S, McMorrow ML, et al. The burden of influenza and RSV among inpatients and outpatients in rural Western Kenya, 2009–2012. *PLoS One* 2014; 9:e105543.
22. Guo RN, Zheng HZ, Huang LQ, et al. Epidemiologic and economic burden of influenza in the outpatient setting: a prospective study in a subtropical area of China. *PLoS One* 2012; 7:e41403.

23. Fowlkes A, Giorgi A, Erdman D, Temte J, Goodin K, Di Lonardo S, et al. Viruses associated with acute respiratory infections and influenza-like illness among outpatients from the Influenza Incidence Surveillance Project, 2010–2011. *J Infect Dis* **2014**; 209: 1715–25.
24. Homaira N, Luby SP, Petri WA, et al. Incidence of respiratory virus-associated pneumonia in urban poor young children of Dhaka, Bangladesh, 2009–2011. *PLoS One* **2012**; 7: e32056.
25. Gresh L, Kuan G, Sanchez N, et al. Burden of influenza and influenza-associated pneumonia in the first year of life in a prospective cohort study in Managua, Nicaragua. *Pediatr Infect Dis J* **2016**; 35:152–6.
26. Forshey BM, Laguna-Torres VA, Vilcarrero S, et al. Epidemiology of influenza-like illness in the Amazon Basin of Peru, 2008–2009. *Influenza Other Respir Viruses* **2010**; 4: 235–43.
27. Pollett S, Nelson MI, Kasper M, et al. Phylogeography of influenza A(H3N2) virus in Peru, 2010–2012. *Emerg Infect Dis* **2015**; 21: 1330–8.
28. Clara W, Armero J, Rodriguez D, et al. Estimated incidence of influenza-virus-associated severe pneumonia in children in El Salvador, 2008–2010. *Bull World Health Organ* **2012**; 90: 756–63.
29. Azziz-Baumgartner E, Alamgir AS, Rahman M, et al. Incidence of influenza-like illness and severe acute respiratory infection during three influenza seasons in Bangladesh, 2008–2010. *Bull World Health Organ* **2012**; 90: 12–9.
30. Bhat-Schelbert K, Lin CJ, Matambanadzo A, Hannibal K, Nowalk MP, Zimmerman RK. Barriers to and facilitators of child influenza vaccine—perspectives from parents, teens, marketing and healthcare professionals. *Vaccine* **2012**; 30:2448–52.
31. Descalzo MA, Clara W, Guzmán G, et al. Estimating the burden of influenza-associated hospitalizations and deaths in Central America. *Influenza Other Respir Viruses* **2016**; 10:340–5.
32. Whitley RJ, Monto AS. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. *J Infect Dis* **2006**; 194(suppl 2): S133–8.
33. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the community-dwelling elderly. *N Engl J Med* **2007**; 357:1373–81.
34. Hodgson D, Baguelin M, van Leeuwen E, et al. Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in England and Wales: a modelling and cost-effectiveness analysis. *Lancet Public Health* **2017**; 2:e74–81.
35. Pebody RG, Green HK, Andrews N, et al. Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season. *Euro Surveill* **2014**; 19. pii:20823.
36. Hirve S, Chadha M, Lele P, et al. Performance of case definitions used for influenza surveillance among hospitalized patients in a rural area of India. *Bull World Health Organ* **2012**; 90: 804–12.
37. Hayward AC, Fragaszy EB, Bermingham A, et al; Flu Watch Group. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. *Lancet Respir Med* **2014**; 2:445–54.
38. Horby P, Mai le Q, Fox A, et al. The epidemiology of interpandemic and pandemic influenza in Vietnam, 2007–2010: the Ha Nam household cohort study I. *Am J Epidemiol* **2012**; 175: 1062–74.

**Peru Influenza Cohorts Working Group**

Ernesto Ortiz, Carolina Guevara, Claudia Guezala, Carlos Figueroa, Sebastian Loli, Alberto Laguna, Eric Halsey, Erik Reaves, Maya Williams, Christopher Mores, Wesley Campbell, Hugo H. García, Armando E. González.